Loading clinical trials...
Loading clinical trials...
A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM313 in Healthy Overweight and Obese Adult Participants
Conditions
Interventions
NGM313
Placebo
Locations
1
Australia
NGM Clinical Study Site
Melbourne, Victoria, Australia
Start Date
February 1, 2016
Primary Completion Date
April 1, 2017
Completion Date
April 1, 2017
Last Updated
September 14, 2017
NCT01143454
NCT07472881
NCT07010757
NCT06989203
NCT06223555
NCT07237750
Lead Sponsor
NGM Biopharmaceuticals, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions